Aurora Cannabis (TSE:ACB) Stock Rating Upgraded by BMO Capital Markets

Aurora Cannabis (TSE:ACB) was upgraded by equities researchers at BMO Capital Markets to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities analysts have also weighed in on ACB. Canaccord Genuity Group lowered their target price on Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. TD reduced their price target on Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating for the company in a research note on Friday, June 12th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of C$7.17.

Aurora Cannabis Price Performance

TSE:ACB opened at C$4.15 on Wednesday. The company has a market cap of C$257.06 million, a P/E ratio of -1.94 and a beta of 0.25. The firm’s fifty day moving average price is C$4.08 and its two-hundred day moving average price is C$4.63. Aurora Cannabis has a one year low of C$3.59 and a one year high of C$9.33. The company has a debt-to-equity ratio of 4.30, a current ratio of 5.36 and a quick ratio of 2.48.

Aurora Cannabis (TSE:ACB) last announced its earnings results on Wednesday, August 5th. The company reported C($0.07) EPS for the quarter. The company had revenue of C$67.55 million for the quarter. Aurora Cannabis had a negative return on equity of 5.21% and a negative net margin of 9.53%. Equities analysts expect that Aurora Cannabis will post -0.22 earnings per share for the current year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.